Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

First filed December 23, 2020, Updated July 2022; Recruiting

The purpose of this  Phase 2 study is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active SLE.

This study is being offered at 20 LuCIN sites – institutions that are members of the Lupus Clinical Investigators Network managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance.

To Learn More Contact
Amgen Call Center at 866-572-6436 or email medinfo@amgen.com

ClinicalTrials.gov identifier (NCT number): NCT04680637

Learn More

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up